London-listed Hikma Pharmaceuticals (LSE: HIK) and UK company Arecor have agreed to co-develop a new, ready-to-use injectable medicine in the USA.
The product, which will be announced prior to launch, is being developed using Arecor’s drug formulation technology platform Arestat, which enhances the properties of approved therapeutic proteins and peptides to deliver new reformulations of existing, complex products.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze